Revolution Medicines, Inc.
RVMD
Rankning i aktier
#581
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Aktiekurs
$196.16
Senast synkroniserad: 2026-10-20
Marknadsvärde
$42.04B
Förändring (1 dag)
7.69%
Förändring (1 år)
266.72%
Land
US
Handel Revolution Medicines, Inc. (RVMD)
Kategori
Healthcare
P/B-tal för Revolution Medicines, Inc. (RVMD)
P/B-tal per October 2026 TTM: 15.66
Enligt Revolution Medicines, Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 15.66. I slutet av 2023 hade företaget ett P/B-tal på 1.78.
Historik för P/B-tal för Revolution Medicines, Inc. från 2017 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 15.66 | 383.31% |
| 2024 | 3.24 | 82.27% |
| 2023 | 1.78 | -36.60% |
| 2022 | 2.80 | -7.84% |
| 2021 | 3.04 | -45.25% |
| 2020 | 5.55 | -19.62% |
| 2019 | 6.91 | -36.63% |
| 2018 | 10.91 | -95.31% |
| 2017 | 232.64 | 0.00% |
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 6.251 | -60.08% |
US
|
|
| 13.2547 | -15.36% |
US
|
|
| 4.208 | -73.13% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -60.52% |
NL
|
